Argireline (acetyl Hexapeptide-3)
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Argireline is the best-known and longest-marketed of the “topical Botox” peptide family — a hexapeptide formulated into serums and creams as a topical alternative to injectable neuromodulators for softening expression lines (forehead lines, crow’s feet, frown lines).
What does it do in my body?
Argireline competes with SNAP-25 for its position in the SNARE complex, the molecular machinery that docks neurotransmitter vesicles at the neuromuscular junction. By displacing SNAP-25, it reduces vesicle docking and acetylcholine release, so the muscle contracts less intensely — the same target signal that botulinum toxin blocks at the muscle, approached from a topical serum instead of an injection.
How can it help me?
- Where the science stands: Public profile: 0 PubMed studies, 0 human trials (Anecdotal). OHM’s internal 0035 grading cites manufacturer topical RCTs (~10–30% wrinkle-depth reduction over 4–8 weeks, Lubrizol)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No specific adverse-effect data was captured in the source profile. As a topical-only cosmetic ingredient, the family-wide safety read applies: topical delivery has a benign safety record because it isn’t injected or absorbed systemically in meaningful amounts.
Regulatory status: Argireline is sold as a cosmetic-grade topical ingredient in commercial skincare formulations — legal OTC, not an FDA-reviewed drug and not a peptide sold through research-peptide channels.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Argireline is a topical-only ingredient. Typical cosmetic formulation is 5–10% in leave-on serums, per general cosmetic-industry convention. There is no injectable or systemic use case for this compound.
What should I avoid combining — and what's synergistic?
Argireline (acetyl Hexapeptide-3) doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for Argireline (acetyl Hexapeptide-3) yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
The original “topical Botox” peptide — decades of use in leave-on serums, a plausible SNARE-complex mechanism, and a public evidence record that’s thinner than the marketing. Honest read: real mechanism, gentle real-world effect, and the strongest efficacy numbers come from manufacturer trials, not independent PubMed RCTs.
| Class | Neuromuscular “Botox-like” relaxer — topical cosmetic peptide |
| Mechanism (one line) | Competes with SNAP-25 in the SNARE complex → less acetylcholine release at the neuromuscular junction → gentler muscle contraction |
| Evidence base | Public profile: 0 PubMed studies, 0 human trials (Anecdotal). OHM’s internal 0035 grading cites manufacturer topical RCTs (~10–30% wrinkle-depth reduction over 4–8 weeks, Lubrizol) |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Argireline is the best-known and longest-marketed of the “topical Botox” peptide family — a hexapeptide formulated into serums and creams as a topical alternative to injectable neuromodulators for softening expression lines (forehead lines, crow’s feet, frown lines).
How it works
Argireline competes with SNAP-25 for its position in the SNARE complex, the molecular machinery that docks neurotransmitter vesicles at the neuromuscular junction. By displacing SNAP-25, it reduces vesicle docking and acetylcholine release, so the muscle contracts less intensely — the same target signal that botulinum toxin blocks at the muscle, approached from a topical serum instead of an injection.
What the research shows
The public record and OHM’s internal grading tell two different stories, and both are worth knowing:
- Public profile: zero PubMed-indexed studies and zero human trials — graded Anecdotal.
- OHM’s 0035 categorization pass graded Argireline Tier C / green and recommend-eligible, on the basis of “small human topical RCTs in wrinkle-depth reduction (~10–30% on facial wrinkles over 4–8 weeks)” attributed to manufacturer (Lubrizol) research.
That gap — real formulator data that doesn’t show up in the independent PubMed record — is itself the honest story here: the evidence likely exists, but it’s largely industry-held rather than independently published.
Real-world protocol
Argireline is a topical-only ingredient. Typical cosmetic formulation is 5–10% in leave-on serums, per general cosmetic-industry convention. There is no injectable or systemic use case for this compound.
Side effects & management
No specific adverse-effect data was captured in the source profile. As a topical-only cosmetic ingredient, the family-wide safety read applies: topical delivery has a benign safety record because it isn’t injected or absorbed systemically in meaningful amounts.
Regulatory status
Argireline is sold as a cosmetic-grade topical ingredient in commercial skincare formulations — legal OTC, not an FDA-reviewed drug and not a peptide sold through research-peptide channels.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing manufacturer (Lubrizol) topical RCTs.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: SNAP-8 · Vialox · Syn-Ake · Pentapeptide-18
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing manufacturer (Lubrizol) topical RCTs.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: SNAP-8 · Vialox · Syn-Ake · Pentapeptide-18